Sanjay Mukhopadhyay

1. Introducing a new thread: super basic lung pathology for PGY1s, with arrows. If you are a PGY1, leave a comment and I will tag you in a future post. A hamartoma is a disorganized mix of overgrown normal tissues (in their normal location) that creates a mass. Good news: they are benign! #pathology #pulmpath #tweetorial #pathtweetorial #sblppgy1

@ArBghyaBandyopa5 BAL fluid cytology: PAS stain (40× and 100x): Pulmonary alveolar proteinosis: Esosinophilic globules, PAS +, average 50 micron in diameter.

4/ Next up, the 2 pathology trainee awards for #PathTweetAward 2025. This year both the winning tweets picked by the screening judges and final judges were by Dr. Miruna Popescu (@MirunaPopescu13) !! Vote for the tweet you think was the best of the year

1/ Here are the 4 winners for the 8th Annual #PathTweetAward (2025)! All will get awards but we need to rank winner and runner up so pls VOTE in the poll below. First up, open category. Please scroll down in the thread to see the tweets followed by trainee awardees. @cebulka26

@m_janelee Yep. And book a nice hotel that you spend so little time in! And taking a 15 hour flight, two connections, only to give a 20 minute talk.

Very interesting!

@Teclis82 @YouTube Thank you Brian! 🙏🏾🙏🏾

@smlungpathguy @YouTube This gives a great framework for approaching lung tumors - I also liked the tie-ins to commonality/rarity. Thanks for sharing

Tumors of the Lung with Sanjay Mukhopadhyay, MD youtu.be/4DzXgspyFwc?si… via @YouTube

#PulmPath #ThoracicPath #Pathresidents Awesome lectures from our Guru @smlungpathguy Thank you 🙏🏻🙏🏻 youtu.be/4DzXgspyFwc?si…

#Pathbugs #crittersontwitter

@slusagar #PathTweetAward

#GUpath urinary bladder bx called urothelial carcinoma in situ (correctly) CK20: called positive p53: called "negative/noncontributory" (when in fact 👀null phenotype pattern staining👉🏽"positive" result; better to say "mutant pattern" or "null phenotype")

#Pathbugs #crittersontwitter

journals chasing down a potential Reviewer to take on the manuscript days before #USCAP2026 starts

Would make a nice PowerPoint slide

academic conferences are crazy because it’s like Let’s go to the most beautiful place in the world and then look at powerpoints for 12 straight hours

lol!!

@ScottBikeethan @smlungpathguy Very well said - it applies to other organ systems such as my GU! We did a workshop at the 2024 IAP in Mexico just about this! Publications summarizing this coming out soon!

Every Federer needs a Rafa! 🙏🏾🥰

un-necessary costs to the patients and healthcare systems. Hope to see you there! @smlungpathguy @CLEClinicLabs @ccfpathology #pathology @ISBSTP @TheUSCAP #sarcoma #orthopedics #BSTpath @JMGardnerMD

and immunophenotype, understanding that molecular events alone should never define an entity. I also seek to provide personal guidelines for when molecular testing is not needed (e.g. classic myositis ossificans, clear cell sarcoma, etc.) and ultimately results in

small number of newly defined entities being recognized. Molecular events should not be considered pathognomonic, and we now recognize identical gene fusions in tumors with entirely different and distinct morphology/immunophenotype and clinical behaviors

majority of tumors in our classification system were described and well documented prior to being also confirmed as having molecular drivers. For sure, molecular testing has helped clarify boundaries, but the classification system has expanded not contracted, with only a